1. Liposomes loaded with daunorubicin and an emetine prodrug for improved selective cytotoxicity towards acute myeloid leukaemia cells.
- Author
-
Reiten IN, Giraud F, Augedal TT, Førde JL, Moreau P, Gundersen ET, Chapron D, Legrand FX, Anizon F, and Herfindal L
- Subjects
- Humans, Animals, Cell Line, Tumor, Cell Survival drug effects, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic pharmacology, Antibiotics, Antineoplastic chemistry, Liposomes, Prodrugs chemistry, Prodrugs administration & dosage, Prodrugs pharmacology, Daunorubicin administration & dosage, Daunorubicin pharmacology, Emetine administration & dosage, Emetine pharmacology, Emetine chemistry, Leukemia, Myeloid, Acute drug therapy, Zebrafish
- Abstract
The backbone of induction therapy in acute myeloid leukaemia (AML) is to use an anthracycline in combination with cytarabine. Despite recent advances in AML therapy, this treatment remains the standard, and it has been largely unchanged for decades. There are few curative options for patients unfit for this treatment. The anti-protozoal agent emetine improves efficacy of anthracycline treatment towards AML in vitro and in vivo but the effect is more potent when emetine is administered 30 minutes after anthracyclines. To delay the onset of protein synthesis inhibition we produced a novel inactive emetine prodrug and co-encapsulated this with the anthracycline daunorubicin (DNR) in liposomes. Nanoencapsulation protects the prodrug from degradation in the blood and ensure simultaneous delivery of both drugs to cancer cells. The prodrug concept will delay the onset of action of emetine relative to DNR. In AML cells, the combination of DNR and the emetine-prodrug in liposomes increased cytotoxicity compared to liposomes with DNR and native emetine. Liposomes loaded with the emetine prodrug did not show increased toxicity towards non-cancerous cell lines and zebrafish larvae. In patients, a liposomal formulation such as that presented herein could allow for a reduced DNR dose without compromising efficacy, thereby reducing toxic side effects and enabling improved therapy for patients not fit for current treatment options., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Lars Herfindal reports financial support was provided by Childhood Cancer Association. Edvin Tang Gundersen reports financial support was provided by Western Norway Regional Health Authority. Ingeborg N Reiten reports financial support was provided by Research Council of Norway. Francois-Xavier Legrand reports financial support was provided by National Centre for Scientific Research. David Chapron reports financial support was provided by National Centre for Scientific Research. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper]., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF